Latest Stories
Featured Stories
Explore inspiring journeys of recovery and resilience as patients share their experiences with Padaav’s root-cause-focused, evidence-based Ayurvedic treatments, highlighting the power of personalized care and holistic healing.
Feedback
All Stories
Delve into the heartfelt experiences of patients who have transformed their health and lives with Padaav’s research-backed Ayurvedic care, showcasing the impact of addressing root causes for lasting recovery.
Vivaan Guleria
Acute on Chronic Pancreatitis
Dharamshala, Himachal Pradesh
This story is a powerful testament to resilience and hope. It narrates the journey of Vivaan Gule…
Robin Singh
Acute Necrotizing Pancreatitis
Kurukshetra, Haryana
This story narrates the journey of Robin Singh, a healthy, 30-year-old businessman and gym-goer, …
Surendra Rathaur
Acute Pancreatitis
Ahmedabad, Gujarat
Ahmedabad, Gujarat, India — Surendra Rathaur, a 34-year-old Senior Software Engineer from A…
Samip Desai
Chronic Calcific Pancreatitis
Ahmedabad, Gujarat
Ahmedabad, Gujarat, India — Samip Desai, a 38-year-old restaurateur from Ahmedabad, embarke…
Hardi Nayak
Acute Pancreatitis
Gandhinagar, Gujarat
Gandhinagar, Gujarat, India — Hardi Nayak, a 12-year-old student from Gandhinagar, found he…
Raj Khanapara
Chronic Pancreatitis
Rajkot, Gujarat
Rajkot, Gujarat, India — For Raj Khanapara, a 26-year-old businessman from Rajkot, the onse…
Research
Our Research
At Padaav, alongside delivering unparalleled patient care and promoting holistic health, we are committed to advancing Ayurveda by actively participating in research and contributing to its growing body of knowledge.
CA19-9 lowering effect of Ayurvedic Mineral Complex in the patients of Chronic Pancreatitis
CA19-9, a marker for pancreatic cancer, is elevated in pancreatitis and some gastrointestinal cancers. An Ayurvedic Mineral Complex (AMC) has shown promise in lowering CA19-9 levels in pancreatitis patients. This finding could lead to further research on AMC as a preventive therapy for pancreatic cancer in such patients. This study reports on 43 pancreatitis patients treated with AMC.
Significant Reduction of Carbohydrate 19-9 Antigen Levels in a Patient of Acute on Chronic Pancreatitis through Ayurvedic Treatment Protocol
A 52-year-old male with recurrent acute necrotizing pancreatitis showed poor response to conventional treatment, leading to weight loss and high CA 19-9 levels. Ayurvedic therapy, including herbal formulations, a balanced diet, and rest, normalized his CA 19-9 levels within 108 days, highlighting its potential for further study.
Acute and Sub acute Toxicity Study of Ayurvedic Formulation (AYFs) Used for Migraine Treatment
This study tested the safety of five Ayurvedic formulations for migraine prevention in rats and mice. Acute and sub-acute toxicity studies showed no toxic effects at doses up to 10 times the human dose. A slight mortality in high-dose groups was unrelated to treatment. The formulations are considered safe, but further chronic toxicity studies are needed.
Ayurvedic treatment protocol in the management of pancreatitis: A nonrandomized observational study
A North Indian clinic treated 1750 recurrent pancreatitis patients (1997–2023) with an ayurvedic Herbo-Mineral Formulation (HMF). Among 916 completing 1-year treatment, attacks reduced by 93%, hospitalizations by 97%, with no adverse effects. Long-term remission supports further clinical trials.
CA19-9 LOWERING EFFECT OF AN AYURVEDIC MINERAL COMPLEX PREPARED USING COPPER, MERCURY AND SULPHUR
Rasa Shastra, an Ayurvedic practice using metals and minerals, has shown that Ayurvedic Mineral Complex (AMC) helps reduce elevated CA19-9 levels in pancreatitis patients. This suggests AMC could be explored as a preventive therapy for pancreatic cancer.
Proof of Efficacy Study to Evaluate an Ayurvedic Formulation in the Treatment of Allergic Rhinitis: An Open Label Randomized Controlled Clinical Trial
A study on 250 patients compared the Ayurvedic formulation IMMBO to a levocetirizine-montelukast combination for allergic rhinitis. IMMBO showed significantly greater improvements in symptoms (TNSS: -5.70 vs. -3.31) and IgE reduction (-351.54 vs. -208.79), demonstrating superior efficacy and safety.